Clinical Trial Update: Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease [Phase 2]

View source ↗

Summary

Phase 2 trial of OBP-301 (Telomelysin) in combination with pembrolizumab and SBRT in head and neck squamous cell carcinoma with inoperable, recurrent or progres…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• OBP-301 (Telomelysin) (Telomelysin)
• Pembrolizumab (pembrolizumab)
• SBRT (stereotactic body radiotherapy)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Head and Neck Squamous Cell Carcinoma With Inoperable Recurrent or Progressive Disease | Phase 2 | Status: TERMINATED | Results posted: 2023-01-11